About: Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study. Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study.
Creator	Fritz, Joëlle Turner, Jonathan Aguayo, Gloria Huiart, Laetitia Ollert, Markus Snoeck, Chantal Abdelrahman, Tamir Beaumont, Katy Gantenbein, Manon Ghosh, Soumyabrata Gomes, Clarissa Hanff, Anne-Marie Hansen, Maxime Kaysen, Anne Krüger, Rejko Meyers, Guilherme Pauly, Claire Pauly, Laure Pavelka, Lukas Perquin, Magali Satagopam, Venkata Schröder, Valerie Stute, Lara Vaillant, Michel
source	MedRxiv
abstract	BACKGROUND: After the World Health Organization declared the outbreak of coronavirus disease to be a public health emergency of international concern on January 30, 2020, the first SARS-CoV-2 infection was detected in Luxembourg on February 29, 2020. Representative population-based data, including asymptomatic individuals for assessing the viral spread and immune response were, however, lacking worldwide. METHODS: Using a panel-based method, we implemented a representative sample of the Luxembourgish population based on age, gender and residency for testing for SARS-CoV-2 infection and antibody status in order to define prevalence irrespective of clinical symptoms. Participants were contacted via email to fill an online questionnaire before biosampling at local laboratories. All participants provided information related to clinical symptoms, epidemiology, socioeconomic and psychological assessments and underwent biosampling, rRT-PCR testing and serology for SARS-CoV-2. RESULTS: We included a total of 1862 individuals in our representative sample of the general Luxembourgish population. Of these, 5 individuals had a current positive result for infection with SARS-CoV-2 based on rRT-PCR. Four of these individuals were oligosymptomatic and one was asymptomatic. Overall we found a positive IgG antibody status in 35 individuals (1.97%), of which 11 reported to be tested positive by rRT-PCR for SARS-CoV-2 previously and showed in addition their IgG positive status also a positive status for IgA. Our data indicate a prevalence of 0.3% for active SARS-CoV-2 infection and an infection rate of 2.15% in the Luxembourgish population between 18 and 79 years of age. CONCLUSIONS: Luxembourgish residents show a low rate of acute infections after 7 weeks of confinement and present with an antibody profile indicative of a more recent immune response to SARS-CoV-2. All infected individuals were oligo- or asymptomatic. Bi-weekly follow-up visits over the next 2 months will inform about the viral spread by a- and oligosymptomatic carriers and the individual changes in the immune profile.
has issue date	2020-05-18(xsd:dateTime)
bibo:doi	10.1101/2020.05.11.20092916
has license	medrxiv
sha1sum (hex)	f92f53af769d35dd045e62f7e96894253d6a58e1
schema:url	https://doi.org/10.1101/2020.05.11.20092916
resource representing a document's title	Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study.
resource representing a document's body	covid:f92f53af769d35dd045e62f7e96894253d6a58e1#body_text
is schema:about of	named entity 'infection' named entity 'detected' named entity 'World Health Organization' named entity 'SARS-CoV-2' named entity 'Luxembourgish' named entity 'immune response' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'online questionnaires' named entity 'Qiagen' named entity 'data set' named entity 'social desirability' named entity 'peer review' named entity 'medRxiv' named entity 'Luxembourg' named entity 'antibody' named entity 'SARS-CoV-2' named entity 'pandemic disease' named entity 'IFR' named entity 'follow-up' named entity 'rRT-PCR' named entity 'general population' named entity 'pseudonymised' named entity 'infection' named entity 'sampling frame' named entity 'serology' named entity 'viral shedding' named entity 'IgG' named entity 'demographic data' named entity 'positive or negative' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'medRxiv' named entity 'electoral district' named entity 'SARS-CoV2' named entity 'SARS-CoV-2' named entity 'follow-up' named entity 'preprint' named entity 'electoral district' named entity 'viral RNA' named entity 'Luxembourg' named entity 'enzyme-linked immunosorbent assay' named entity 'rRT-PCR' named entity 'peer review' named entity 'SARS-CoV-2' named entity 'Computing Platform' named entity 'RNA' named entity 'serological' named entity 'sample size' named entity 'follow-up' named entity 'COVID-19' named entity 'medRxiv' named entity 'Cary, NC' named entity 'specific serology' named entity 'cross-reactivity' named entity 'probability' named entity 'WHO' named entity 'rRT-PCR' named entity 'SARS-CoV-2' named entity 'epidemiological' named entity '95% confidence interval' named entity 'questionnaire'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software